Authors: Zhang JL, Tong AL, Feng YL, Zhao DC, Zhong L, Gao YJ, Song YL, Zhang TP, Li M, Chen YJ.
DOI: 10.3389/fendo.2025.1685806
Abstract Summary
Patients with insulinoma show elevated levels of LEAP2, a newly identified hormone that counteracts ghrelin. This study found LEAP2 correlates with both hyperinsulinemia and obesity in insulinoma patients, and is expressed directly in tumor tissue—suggesting it may play a key role in the metabolic complications of this condition.
Why Brain? đź§
Elevated LEAP2 levels in insulinoma patients correlate with hyperinsulinemia and obesity, with tumor tissue expressing this ghrelin antagonist, revealing potential metabolic mechanisms.
License: CC BY.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
